HER2阳性非小细胞肺癌诊断及治疗进展  

Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer

作　　者：任晨怡 曹赫[2] 郑静[2] 孙文佳 周建娅[2] Chenyi REN;He CAO;Jing ZHENG;Wenjia SUN;Jianya ZHOU(Department of Respiratory Disease,The Fourth Affiliated Hospital,Zhejiang University School of Medicine,Yiwu 322000,China;Department of Respiratory Disease,Thoracic Disease Center,The First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310000,China)

机构地区：[1]浙江大学医学院附属第四医院呼吸与危重症医学科,义乌322000 [2]浙江大学医学院附属第一医院呼吸与危重症医学科,杭州310000

出　　处：《中国肺癌杂志》2023年第4期291-302,共12页Chinese Journal of Lung Cancer

基　　金：浙江省呼吸系统疾病临床医学研究中心基金项目(No.2022E50005)资助。

摘　　要：肺癌是全球最常见的恶性肿瘤,也是癌症死亡的主要原因。人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)阳性非小细胞肺癌(non-small cell lung cancer,NSCLC)是指因HER2基因发生突变、扩增、过表达,导致其功能失调,从而发生的NSCLC。HER2是HER家族中活性最高的受体,可以与其他成员结合形成二聚体,激活多种信号通路,从而调节细胞增殖、分化、迁移和凋亡。在NSCLC中,HER2阳性通常被认为是预后不良的标志。目前HER2阳性NSCLC的诊疗尚未成熟。通常使用免疫组化(immunohistochemistry,IHC)、下一代测序(next generation sequencing,NGS)等方法来检测HER2突变、扩增、过表达这些阳性状态。在先前的研究中,抗肿瘤药物在HER2阳性NSCLC中并未显示出理想的疗效。但近些年来,相关研究表明靶向治疗中的抗体药物偶联物(antibody-drug conjugates,ADCs)和新型酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKIs)对HER2阳性NSCLC显示出较好的抗肿瘤活性。本文归纳了HER2阳性NSCLC的诊断和治疗进展,为后续研究提供参考。Lung cancer is the most common malignancy in the world and the leading cause of cancer death.Human epidermal growth factor receptor 2(HER2)positive non-small cell lung cancer(NSCLC)refers to the NSCLC caused by mutation,amplification or overexpression of the HER2 gene,resulting in its dysfunction.HER2 is the most active receptor in the HER family and can combine with other members to form dimers,which can activate multiple signaling pathways and regulate cell proliferation,differentiation,migration and apoptosis.In NSCLC,HER2 positivity is usually considered a poor prognostic marker.At present,the diagnosis and treatment of HER2-positive NSCLC are not mature.Immunohistochemistry(IHC),next generation sequencing(NGS)and other technologies are often used to detect the positive status of HER2 mutation,amplification or overexpression.In previous studies,antitumor drugs did not show ideal therapeutic effects in HER2-positive NSCLC.However,in recent years,related researches have shown that antibody-drug conjugates(ADCs)and new tyrosine kinase inhibitors(TKIs)in targeted therapy show good antitumor activity against HER2 positive NSCLC.This article summarized the progress in diagnosis and treatment of HER2-positive NSCLC,so as to provide reference for subsequent researches.

关 键 词：肺肿瘤 人表皮生长因子受体2 靶向治疗 

分 类 号：R734.2[医药卫生—肿瘤]